Hemopoietic Recovery and Infectious Complications in Breast Cancer and Multiple Myeloma after Autologous CD34+ Cell-Selected Peripheral Blood Progenitor Cell Transplantation

International Journal of Hematology

Volumn 79, Issue 1, 2004, Pages 85-91

  De Rosa, Luca ^a   Anghel, Gabriel ^a   Pandolfi, Annino ^a   Riccardi, Massimo ^a   Amodeo, Rachele ^a   Majolino, Ignazio ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Breast cancer; CD34+ cell selection; Infectious complications; Multiple myeloma; Peripheral blood progenitor cell transplantation

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BACITRACIN; CARBOPLATIN; CARMUSTINE; CD34 ANTIGEN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUCONAZOLE; GANCICLOVIR; IDARUBICIN; IFOSFAMIDE; ITRACONAZOLE; MELPHALAN; NEOMYCIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VANCOMYCIN; VINCRISTINE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIGEN EXPRESSION; ARTICLE; AUTOGRAFT; AUTOTRANSPLANTATION; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL RENEWAL; CELL SELECTION; CELL TRANSPLANTATION; CELLULITIS; CLINICAL ARTICLE; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; FEMALE; GALLBLADDER DISEASE; HEART ARRHYTHMIA; HEMATOPOIESIS; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; INCIDENCE; INFECTION COMPLICATION; INFECTION RISK; LIVER DYSFUNCTION; LUNG TOXICITY; MULTIPLE MYELOMA; MYCOSIS; NEUROLOGIC DISEASE; NEUTROPHIL; PERIPHERAL CIRCULATION; PHARYNGITIS; PNEUMONIA; STATISTICAL SIGNIFICANCE; STEM CELL; STOMATITIS; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; WHOLE BODY RADIATION;

EID: 0842278677     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02983539     Document Type: Article

References (28)

1. Schiller G, Vescio R, Freytes C, et al. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant. 1998;21:141-145.
2. + cells to support single or tandem high-dose chemotherapy. Blood. 2000;95:2234-2239.
3. + selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999;93:1858-1868.
4. Antman KH, Rowlings PA, Vaugham PW, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870-1897.
5. Shpall EJ, LeMaistre CF, Holland K, et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer receiving high-dose chemotherapy. Blood. 1997;90:4313-4320.
6. +-selected autologous peripheral blood stem cell transplantation (PBSCT) in patients with poor-risk hematological malignancies and solid tumors: a single-centre experience. Bone Marrow Transplant. 1997;20:827-834.
7. + peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Br J Haematol. 1999;104:382-391.
8. + cells: analysis of predictive factors and comparison with unselected progenitor transplants. Br J Haematol. 2000;108:105-115.
9. Nishio M, Koizumi K, Endo T, Fujimoto K, Koike T, Sawada K. Diminished T-cell recovery after CD34 selected autologous peripheral blood stem cell transplantation increases the risk of cytomegalovirus infection. Haematologica. 2001;86:667-668.
10. + cells. J Hematother Stem Cell Res. 2002;11:983-986.
11. + cell-selected autologous peripheral blood stem cell transplantation. Int J Hematol. 1999;70:193-199.
12. +-selected PBPC after high-dose chemotherapy in breast cancer patients is associated with prolonged recovery time and increased infectious complications. J Hematother Stem Cell Res. 1999;8:387-391.
13. Miyamoto T, Gondo H, Miyoshi Y, et al. Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol. 1998;100:348-350.
14. Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood. 1999;94:4029-4035.
15. Schiller GJ, Vescio R, Berenson J. Cytomegalovirus infection following transplantation of autologous CD34-selected progenitor cells [letter]. Blood. 2000;96:1194.
16. Nachbaur D, Kropshoffer G, Feichtinger H, Allerberger F, Niederweiser D. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBPCT): treatment with paramomycin, azithromycin and recombinant human interleukin-2. Bone Marrow Transplant. 1997;19:1261-1263.
17. Crippa FL, Holmberg L, Carter RA, et al. Infectious complications after autologous CD34-selected peripheral blood progenitor cell transplantation. Biol Blood Marrow Transplant. 2002;8:281-289.
18. + enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation. Bone Marrow Transplant. 2000;26:831-836.
19. Peggs KS, Ings SJ, Kotlaridis PD, et al. Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring [letter]. Blood. 2000;96:369-370.
20. +-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications. Int J Hematol. 2001;74:214-221.
21. Berenson RJ, Bensinger WI, Kalamasz DF, et al. Transplantation of stem cells enriched by immunoadsorption. Prog Clin Biol Res. 1992;377:449-457.
22. + cells from blood stem cells components using the Baxter Isolex system. Bone Marrow Transplant. 1997;21:1253-1262.
23. Ljungman P, De Bock R, Cordonnier C, et al. Practices of cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT. Bone Marrow Transplant. 1993;12:399-403.
24. + cells is as safe as unmanipulated peripheral blood progenitor cells. Bone Marrow Transplant. 2001;28:849-857.
25. + cells transplanted, diagnosis and type of conditioning regimen. Ann Hematol. 1998;77(suppl 1):A5.
26. Sezer O, Eucker J, Bauhuis C, Schweigert M, Luftner D, Kalus U. Patients with malignant lymphomas experience a higher rate of documented infections than patients with breast cancer after high-dose chemotherapy with autologous peripheral stem cell transplantation. Ann Hematol. 2000;79:627-630.
27. Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 2001;27:525-529.
28. Barton TD, Collis T, Stadtmauer EA, Schuster MG. Infectious complications after autologous bone marrow transplantation for treatment of breast cancer. Clin Infect Dis. 2001;32:391-395.